Peptide Legality Map 2026: What's Legal, Banned, and Gray Area
By Theo Park · Editor, Privacy & Safety
Updated Jun 2026Informational only. Not medical or legal advice. The peptides described are not FDA-approved for the general clinical uses discussed. Federal and state regulatory status is in active flux — the HHS announcement is intent, not rulemaking, and the formal FDA list update has not posted as of this writing. Verify with a licensed clinician and a healthcare attorney before acting on anything in this article.
Quick Answer
- On Feb 27 2026, HHS announced 14 of 19 restricted peptides will move from FDA Cat 2 to Cat 1
- As of June 2026 the formal FDA rulemaking has still not posted in the Federal Register
- Peptide Sciences (largest US gray-market vendor) voluntarily shut down on March 6 2026
- 5 peptides remain restricted: Melanotan II, GHRP-2, GHRP-6, PEG-MGF, Cathelicidin LL-37
Last updated: June 2026
Informational only. Not medical or legal advice. The peptides described are not FDA-approved for the general clinical uses discussed. Federal and state regulatory status is in active flux — the HHS announcement is intent, not rulemaking, and the formal FDA list update has not posted as of this writing. Verify with a licensed clinician and a healthcare attorney before acting on anything in this article.
The regulatory landscape for peptides in the United States went through its most dramatic shift in years on February 27, 2026, when HHS Secretary Robert F. Kennedy Jr. announced a sweeping reclassification of 14 previously restricted peptides (HHS announcement coverage, 2026). Nearly four months later, the details remain in flux. This guide maps the complete legal status of every major peptide as of June 2026.
Are peptides legal to buy and use in the United States in 2026?
Conditionally — depending on which peptide, where you obtain it, and your status as a licensed prescriber, patient, or seller. FDA-approved peptides (semaglutide, tirzepatide, tesamorelin, PT-141 / Vyleesi, oxytocin) are legal as prescribed Rx drugs. Five Cat 1-eligible compounding peptides (sermorelin, glutathione, NAD+, PT-141, oxytocin) are legal when compounded under a valid physician prescription. The 14 peptides announced on February 27, 2026 (BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, semax, selank, thymosin alpha-1, AOD-9604, DSIP, epithalon, KPV, MOTS-c, kisspeptin-10) remain technically Cat 2 until the Federal Register notice posts — Kennedy's "within weeks" statement is now ~14 weeks overdue. Five peptides remain Cat 2 with no announced reclassification: melanotan II, GHRP-2, GHRP-6, PEG-MGF, and cathelicidin LL-37. Gray-market vendor sales remain technically illegal as "unapproved drugs" under FD&C Act § 505 — and FDA enforcement against vendors has escalated sharply since late 2024.
What is the FDA Category 2 list and why does it matter?
Category 2 is the FDA "do not compound" list — bulk drug substances that licensed 503A pharmacies cannot compound because the FDA has identified safety concerns warranting further review. In September 2023, the FDA added 19 peptide bulk drug substances to Category 2, effectively banning them from compounding (FDA 503A list, 2024). That single action triggered the current regulatory battle and the rise of the "research use only" gray-market vendor model. Category 1 substances may be compounded by 503A pharmacies for individual patients. Category 3 substances have insufficient data — neither approved nor explicitly banned. The September 2024 removal of five peptides (AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1, selank) from Cat 2 did not restore compounding access; the peptides were referred to the Pharmacy Compounding Advisory Committee (PCAC), which reviewed them in October and December 2024.
What happened to Peptide Sciences and the research-chemical vendors?
On March 6, 2026, Peptide Sciences — the largest US gray-market peptide vendor, doing ~$7.4M monthly online sales as of December 2025 per Grips Intelligence — voluntarily shut down all operations. The shutdown was the culmination of over a year of escalating FDA enforcement. December 2024: warning letters to four research peptide vendors (Prime Peptides, Xcel Peptides, SwissChems, Summit Research) for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs. January 2025: International Trade Commission General Exclusion Order blocking tirzepatide imports (USITC GEO, 2025). February 2025: FDA declared the semaglutide shortage resolved, removing the compounding rationale for GLP-1 peptides. June 2025: FDA raided Amino Asylum, the second-largest US research peptide vendor, which subsequently went offline. The "research use only" gray-market model is collapsing. Independent testing by Finnrick Labs flagged 37 retatrutide samples that failed identity, purity, or contamination tests (The Peptide List, 2025).
<a id="legality-table"></a>
Complete US peptide legality table (June 2026)
| Peptide | FDA / Cat status | Legal under physician Rx? | WADA / sport status | Cost-per-month (legitimate channel) |
|---|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | Approved Rx | Yes — branded only; compounding ended Feb 2025 | Not prohibited | $1,000-$1,400 retail |
| Tirzepatide (Mounjaro, Zepbound) | Approved Rx | Yes — branded only; compounding restricted; ITC GEO on imports | Not prohibited | $1,000-$1,200 retail |
| Tesamorelin (Egrifta SV / WR) | Approved Rx | Yes — branded; compounding rarely | Prohibited (GH secretagogue) | $5,500-$11,000 |
| PT-141 (Vyleesi / bremelanotide) | Approved Rx | Yes — branded + Cat 1 compounded | Not prohibited | $300-$600 compounded |
| Oxytocin | Approved Rx | Yes — branded + Cat 1 compounded | Not prohibited | $40-$120 compounded |
| Sermorelin | Cat 1 (compounded) | Yes — 503A/503B compounded | Prohibited (GH secretagogue) | $200-$500 compounded |
| Glutathione, NAD+ | Cat 1 | Yes — Rx required for injectable | Not prohibited | $150-$400 |
| BPC-157 | Cat 2 (Feb 2026 announced for Cat 1, not formalized) | Not yet | Prohibited at all times (S0) | Not legitimately available |
| TB-500 (Tβ4 fragment) | Cat 2 (announced for Cat 1, not formalized) | Not yet | Prohibited at all times (S0) | Not legitimately available |
| CJC-1295 | Cat 2-withdrawn, PCAC reviewed | Not yet | Prohibited (GH secretagogue) | Not legitimately available |
| Ipamorelin | Cat 2-withdrawn, PCAC reviewed | Not yet | Prohibited (GH secretagogue) | Not legitimately available |
| GHK-Cu (injectable) | Cat 2 (announced for Cat 1) | Not yet (topical cosmetic OK) | Not currently on prohibited list | N/A (topical cosmetic legal) |
| Thymosin alpha-1 | Cat 2-withdrawn, PCAC reviewed; approved as Zadaxin in 30+ countries | Not in US | Not currently prohibited | N/A |
| AOD-9604 | Cat 2-withdrawn, PCAC reviewed | Not yet | Prohibited (GH-derived) | Not legitimately available |
| Selank, Semax | Cat 2 (announced for Cat 1) | Not yet | Not currently prohibited | Not legitimately available |
| DSIP, Epithalon, KPV, MOTS-c, Kisspeptin-10 | Cat 2 (announced for Cat 1) | Not yet | Variable | Not legitimately available |
| Melanotan II | Cat 2, NOT in reclassification | No | Prohibited | Not legitimately available |
| GHRP-2, GHRP-6 | Cat 2, NOT in reclassification | No | Prohibited (GH secretagogue) | Not legitimately available |
| PEG-MGF | Cat 2, NOT in reclassification | No | Prohibited | Not legitimately available |
| Cathelicidin LL-37 | Cat 2, NOT in reclassification | No | Not currently prohibited | Not legitimately available |
| MK-677 / Ibutamoren | Cat 2 / PCAC reviewed; not a peptide | No | Prohibited (oral GH secretagogue) | Not legitimately available |
For specifics on the BPC-157 reclassification, see our where to buy peptides legally guide. For the underlying chemistry comparison, see BPC-157 vs TB-500: which heals faster?.
Which peptides are still banned after the February 2026 reclassification announcement?
Five peptides were NOT included in the HHS reclassification and remain on Category 2: Melanotan II, GHRP-2, GHRP-6, PEG-MGF, and Cathelicidin LL-37.
| Peptide | Primary use | Why still restricted |
|---|---|---|
| Melanotan II | Tanning, sexual function | Cardiovascular effects, melanoma risk concerns, uncontrolled pigmentation |
| GHRP-2 | Growth hormone secretion | Elevated cortisol and prolactin |
| GHRP-6 | GH secretion, appetite | Strong appetite stimulation, cortisol elevation |
| PEG-MGF (pegylated MGF) | Muscle growth, recovery | Limited clinical evidence, theoretical tumor-growth concern |
| Cathelicidin LL-37 | Antimicrobial, immune defense | Limited human safety data for systemic use |
The five Cat 2 peptides cannot be legally compounded for human use. Possession by individuals is generally not prosecuted but distribution is illegal as unapproved drugs.
What does the WADA prohibited-substance list say about peptides?
The World Anti-Doping Agency prohibits BPC-157, TB-500, all growth-hormone secretagogues (CJC-1295, ipamorelin, sermorelin, GHRP-2/6, AOD-9604, MK-677), and tesamorelin at all times — regardless of FDA compounding status. USADA explicitly states BPC-157 "creates risk for athletes" regardless of its compounding legality (USADA, 2025). GHK-Cu, selank, and semax are not currently on the WADA prohibited list (WADA 2026 list). PT-141 (bremelanotide), oxytocin, glutathione, and NAD+ are not currently prohibited. Athletes subject to WADA / USADA / NCAA / pro-league testing should check the USADA GlobalDRO database before considering any peptide, including FDA-approved ones — a compounding-legal peptide can still trigger a doping violation. Independent of WADA, MLB, NFL, and many other US pro leagues align with WADA on peptide prohibitions.
State-level regulations layered on top of federal
State boards of pharmacy add their own regulations that affect access on top of federal FDA classification:
Restrictive frameworks: California (aggressive Board of Pharmacy enforcement; even with Cat 1 reclassification, expect California to be slow); New York (additional state licensing for compounding pharmacies, patient-specific compounding required); Massachusetts (strict regulations post-2012 NECC outbreak).
Permissive frameworks: Florida (numerous compounding pharmacies and peptide clinics); Texas (large compounding pharmacy industry); Arizona (streamlined licensing, telemedicine-friendly).
Active legislation in 2026: Tennessee (legislation to explicitly protect physician-prescribed peptide therapy); Utah ("right to try" expansion considered for Cat 1 peptides); Idaho (minimal state-level restrictions beyond federal).
Is BPC-157 legal to buy and use in the United States right now?
No — as of June 2026, BPC-157 is still on FDA Category 2 and cannot legally be compounded for human use. The February 27, 2026 HHS announcement that 14 peptides including BPC-157 will move from Cat 2 to Cat 1 is intent, not rulemaking — the formal Federal Register notice has not posted. Selling BPC-157 as a research chemical for human use is illegal under FD&C Act §505 as an unapproved drug. WADA prohibits BPC-157 at all times in sport. The most legitimate path right now is to consult a licensed physician and wait for the formal Federal Register update before discussing a compounded prescription. For the underlying research base, see our top 10 BPC-157 research studies review and our BPC-157 vs TB-500 comparison for injury recovery.
Are compounded GLP-1 peptides legal in 2026?
Largely no — as of June 2026 the semaglutide and tirzepatide compounding pathways have closed. The FDA declared the semaglutide shortage resolved in February 2025, ending the FD&C Act §503A and §503B shortage exception that had allowed 503B outsourcing facilities and 503A pharmacies to compound copycats during the 2022-2024 shortage. Tirzepatide compounding was further restricted by the January 2025 ITC General Exclusion Order blocking imports of bulk tirzepatide. As of June 2026, only branded semaglutide (Ozempic, Wegovy, Rybelsus) and branded tirzepatide (Mounjaro, Zepbound) are legitimately available. For deeper analysis see Compounded GLP-1 peptides: legal and safety status and our compounded vs brand GLP-1 503A/503B landscape guide.
Research-chemical vendors — the legal and quality reality
A 2024 JAMA Network Open study tested 50 peptide products from online research vendors and found 68% did not contain the labeled amount of the active peptide (ranging 0% to 187% of labeled dose), 12% contained bacterial endotoxins above acceptable limits, and 22% contained undisclosed additives or contaminants (Peptide testing analysis, 2024). Independent testing by Finnrick Labs in 2025 corroborated these findings, with 37 retatrutide samples receiving failing grades.
The legal risk has hardened. Vendors face FD&C Act § 331(d) liability for selling "unapproved new drugs." Buyers face customs seizure on imports (especially tirzepatide post-ITC GEO) and the loss of the "research use only" defense — which the FDA explicitly rejected in its December 2024 warning-letter campaign. Federal criminal charges against peptide-vendor principals are now a documented pattern (AMC Defense Law, 2026).
Timeline: 2023 through expected 2026 progress
| Date | Event |
|---|---|
| September 2023 | FDA adds 19 peptides to Cat 2 |
| September 2024 | FDA removes 5 peptides from Cat 2 after nomination withdrawals |
| Oct-Dec 2024 | PCAC reviews removed peptides + ibutamoren, kisspeptin-10 |
| December 2024 | FDA warning letters to 4 research peptide vendors |
| January 2025 | ITC General Exclusion Order on tirzepatide imports |
| February 2025 | FDA declares semaglutide shortage resolved |
| June 2025 | FDA raids Amino Asylum; vendor goes offline |
| Feb 27, 2026 | HHS announces 14-peptide reclassification to Cat 1 (intent only) |
| March 6, 2026 | Peptide Sciences voluntarily shuts down |
| Q3-Q4 2026 (expected) | FDA Federal Register notice formalizing the reclassification |
| Q4 2026 (expected) | 503A compounding pharmacies begin offering reclassified peptides |
| Ongoing | State boards align local regulations to federal changes |
How to verify a compounding pharmacy's legitimacy
For compounding pharmacies: check state board licensing (the pharmacy must be licensed in your state); confirm 503A vs 503B status (503B outsourcing facilities have additional FDA oversight); request batch-specific certificates of analysis (COA) from third-party labs; verify PCAB (Pharmacy Compounding Accreditation Board) accreditation — the gold standard. See our peptide vendor quality standards guide for the full evaluation framework. For sourcing context across legitimate channels, see where to buy peptides legally 2026.
Frequently asked questions
Is BPC-157 legal to buy and use in 2026? As of June 2026, BPC-157 is still on FDA Cat 2 — the February 27, 2026 HHS reclassification announcement has not yet been formalized via Federal Register notice. Selling BPC-157 for human use is technically illegal as an unapproved drug. With Peptide Sciences shut down and FDA enforcement escalating, the gray-market path carries growing legal and quality risk.
Can I get TB-500 from a compounding pharmacy right now? Not yet in most cases. The HHS announcement signals TB-500 will return to Cat 1, but formal rulemaking has not completed. Some compounding pharmacies may begin offering TB-500 once the Federal Register notice posts. Ask your physician for their timeline.
Which peptides are still banned after the 2026 reclassification? Five peptides remain Cat 2 and were not included in the reclassification: Melanotan II, GHRP-2, GHRP-6, PEG-MGF, and Cathelicidin LL-37. These cannot be legally compounded.
Do I need a prescription for legal peptides? Yes for any compounded Cat 1 peptide and yes for any FDA-approved peptide drug (semaglutide, tirzepatide, tesamorelin, PT-141, etc.). Research chemicals sold "not for human consumption" do not technically require a prescription, but using them for self-treatment is illegal as unapproved-drug use and carries quality risk.
Will insurance cover compounded peptides? In most cases, no. Compounded medications are rarely covered by standard health insurance. You may be able to use HSA/FSA funds for compounded peptides prescribed by a physician.
Related Reading
- BPC-157 vs TB-500: which heals faster?
- Compounded GLP-1 peptides: legal and safety status
- Where to buy peptides legally 2026
- Peptide vendor quality standards 2026
- Top 10 BPC-157 research studies (2026)
-- The Peptide Front Team
On Google
Get our answers in your Google results.
Add Peptide Front as a preferred source and Google will surface our peptide research more often — in Top Stories and AI answers, marked with a preferred badge. One tap, free, undo anytime.
Add us as a preferred sourceOpens Google's source preferences for peptidefront.com. No sign-up with us — it's a Google setting.